Form 4: Aclaris Therapeutics Director Vincent Milano Reports Transaction in Common Stock

Director Vincent Milano of Aclaris Therapeutics reports the vesting and disposal of 4,660 restricted stock units on June 1, 2024.

Summary

• On June 1, 2024, Vincent Milano, a director of Aclaris Therapeutics, Inc., reported a transaction involving common stock.
• The transaction involved the vesting of 4,660 restricted stock units, each representing a contingent right to receive one share of common stock.
• Following the transaction, Milano's beneficially owned securities include 12,523 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency to investors regarding the actions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, ensuring compliance with SEC regulations.
• The reporting of restricted stock unit vesting and subsequent share ownership is consistent with industry norms for executive compensation and transparency.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• The vesting of restricted stock units can be seen as a form of compensation for the director.

Key Dates